Valuation: Medico Intercontinental Limited

Market Cap 260M 2.69M 2.39M 2.23M 2.03M 3.82M 3.86M 26.78M 10.48M 133M 10.08M 9.87M 424M P/E 2025
7.01x
P/E 2026 -7.97x
Enterprise Value 872M 9.01M 8.03M 7.49M 6.81M 12.82M 12.95M 89.77M 35.13M 444M 33.8M 33.08M 1.42B EV / Sales 2025
0.52x
EV / Sales 2026 1.02x
Free-Float
38.75%
Yield 2025 *
-
Yield 2026 -
08-14 Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
05-22 Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-14 Medico Intercontinental Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
25-08-14 Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-07-14 Medico Intercontinental Limited Approves the Appointment of Puneeta Sharma as Company Secretary and Compliance Officer, Effective from 14 July, 2025 CI
25-05-30 Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025 CI
25-04-22 Medico Intercontinental Limited Announces Resignation of Puneeta Sharma as Company Secretary & Compliance Officer, Effective 22 April, 2025 CI
24-11-14 Medico Intercontinental Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
24-08-13 Medico Intercontinental Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
24-05-25 Medico Intercontinental Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
24-05-25 Medico Intercontinental Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
24-04-25 Medico Intercontinental Limited Announces Resignation of Nikul Dipakbhai Shah as Independent Director CI
24-04-09 Medico Intercontinental Limited Proposes to Incorporate Joint Venture Partnership Firm CI
1 day+4.33%
1 week+6.30%
Current month+6.30%
1 month+4.80%
3 months-9.88%
6 months-8.74%
Current year-35.00%
1 week 24.6
Extreme 24.6
27
1 month 22.4
Extreme 22.4
28.5
Current year 20.61
Extreme 20.61
42.9
1 year 20.61
Extreme 20.61
43
3 years 20.61
Extreme 20.61
122
5 years 20.61
Extreme 20.61
122
10 years 8
Extreme 8
132.1
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2019-08-11
Compliance Officer - 2019-05-31
Director TitleAgeSince
Chairman - 2019-04-07
Director/Board Member 53 2019-03-22
Director/Board Member - 2022-11-13
Change 5-day change 1-year change 3-year change Capi.($)
+4.33%+6.30%-28.16%-68.85% 2.58M
-1.61%+1.08%+38.64%+106.93% 1,060B
-0.76%-3.12%+35.78%+62.70% 623B
+0.39%+4.14%+17.00%+83.77% 480B
-0.29%-2.02%+62.52%+37.06% 352B
-2.03%+1.03%+22.25%+42.16% 345B
-1.92%-1.87%+11.94%+33.20% 274B
-2.36%-3.16%-6.95%+8.68% 249B
-1.37%-3.34%+37.86%+52.33% 223B
+0.17%-1.31%+25.96%+96.82% 182B
Average -0.60%-0.25%+21.69%+45.48% 378.8B
Weighted average by Cap. -0.80%+0.04%+30.57%+68.82%

Financials

2025 2026
Net sales 963M 9.95M 8.87M 8.27M 7.52M 14.16M 14.3M 99.16M 38.8M 491M 37.33M 36.53M 1.57B 846M 8.74M 7.79M 7.27M 6.61M 12.44M 12.57M 87.14M 34.1M 431M 32.81M 32.11M 1.38B
Net income 50.57M 523K 466K 435K 395K 744K 751K 5.21M 2.04M 25.78M 1.96M 1.92M 82.48M -32.01M -331K -295K -275K -250K -471K -475K -3.3M -1.29M -16.31M -1.24M -1.21M -52.2M
Net Debt 142M 1.47M 1.31M 1.22M 1.11M 2.09M 2.11M 14.66M 5.74M 72.55M 5.52M 5.4M 232M 612M 6.32M 5.63M 5.26M 4.78M 8.99M 9.08M 62.99M 24.65M 312M 23.72M 23.21M 998M
Projected Income Statement - Annual - Medico Intercontinental Limited
Logo Medico Intercontinental Limited
Medico Intercontinental Ltd is engaged in the business of trading pharmaceutical products. It provides a platform for all research-based biopharmaceutical companies. Its product categories include Gastro, Uro, Nutrition, Cosmetology, Health devices, Hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE-D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT-4, ZIFT SL-250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM CV SY, RELIBEN SUSP, ZIFT SUSP-200, MGCIPACT EYE DROP, OROFACT-PASTE (lamy), OROFACT MOUTH ULCER GEL, CAMBOGIA, LUBRIACT, HIZEN, and CALAMED LOTION. Its subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, and Azillian Healthcare Private Limited.
Employees
41
Date Price Change Volume
26-10-08 ₹26.00 +4.33% 105
26-10-07 ₹24.92 -5.43% 1,658
26-10-06 ₹26.35 +4.61% 2,331
26-10-05 ₹25.19 +5.88% 4,757
26-10-01 ₹23.79 -2.74% 840
  1. Stock Market
  2. Stocks
  3. ICLF Stock